Business
IGC Pharma Expands Phase 2 CALMA Trial into Colombia's Premier Alzheimer's Research Center
- Adds world renowned GNA site to broaden genetic diversity and strengthen path toward 2026 data catalyst - POTOMAC, MARYLAND / ACCESS Newswire / February 9, 2026 /IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company") today announced the expansion ...
About this update from Igc Pharma, Inc.
[{"type":"text","content":"- Adds world renowned GNA site to broaden genetic diversity and strengthen path toward 2026 data catalyst -","length":107,"tagName":"p"},{"type":"text","content":"POTOMAC, MARYLAND / ACCESS Newswire / February 9, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company") today announced the expansion of its Phase 2 CALMA trial for IGC-AD1 into Colombia, South America, through the addition of Grupo de Neurociencias de Antioquia ("GNA").","length":316,"tagName":"p"},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":"IGC Pharma, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":1504,"height":890,"url":"https://media.zenfs.com/en/accesswire.ca/b04ea78577180501bdd1b46b9be1b3aa"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/gla1.yA4ZCeQLjb6n_1Z3w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTU2ODtjZj13ZWJw/https://media.zenfs.com/en/accesswire.ca/b04ea78577180501bdd1b46b9be1b3aa","width":960,"height":568},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/8_J780qhxQHwH9ULqXu1EA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD0xNDIwO2NmPXdlYnA-/https://media.zenfs.com/en/accesswire.ca/b04ea78577180501bdd1b46b9be1b3aa","width":1200,"height":710}},"href":"https://app.accessnewswire.com/imagelibrary/01ad2f85-c219-4faa-925a-029f7c7cbef0/igc-pharma-inc-2025.png","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"This expansion marks a pivotal operational milestone as IGC enters a region internationally recognized for its unique, genetically linked Alzheimer's population. The GNA site is the latest addition to a clinical network that now spans 23 active sites across 26 locations in the United States and Canada.","length":307,"tagName":"p"},{"type":"text","content":"CALMA is a randomized, double-blind, placebo-controlled Phase 2 study that has now reached approximately 70% of planned enrollment. IGC expects to complete enrollment by mid-2026, the primary operational gating step ahead of database lock and topline results.","length":259,"tagName":"p"},{"type":"text","content":"GNA is internationally recognized for its long-running research into genetically linked Alzheimer's disease and related neurodegenerative conditions, including longitudinal cohorts and biomarker's research. For the Colombia site, Dr. Claudia Ramos, a psychiatrist a...